A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2822
Abstract: Marginal zone lymphomas (MZLs) are indolent yet incurable lymphomas with frequent relapses following therapy. For patients with relapsed/refractory disease, no standard therapies exist. Here we report results of an exploratory phase II study aimed at… read more here.
Keywords: relapsed refractory; marginal zone; trial; bendamustine combination ... See more keywords